title: Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia.
abstract: 18F-FRP170, 1-(2-fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, is a new hypoxia imaging agent for positron emission tomography. This compound was synthesized by 18F-labeling of RP170, which was developed as a new hydrophilic 2-nitroimidazole analog. In the present study, we analyzed dynamic whole-body imaging in healthy volunteers and dynamic tumor imaging in three patients with lung cancer.
  
  
  METHODS
  Four healthy male volunteers and three lung cancer patients were enrolled in this study. Volunteers underwent dynamic whole-body scans just after injection of 18F-FRP170 for about 90 min, while the lung cancer patients underwent dynamic tumor imaging for about 60 or 120 min. Data are expressed as standardized uptake values (SUV). Regions of interest were placed over images of each organ or tumor to generate time-SUV curves.
  
  
  RESULTS
  The series of dynamic whole-body scans showed rapid elimination of 18F-FRP170 from the kidneys following elimination from the liver. Very low physiological uptake was observed above the diaphragm. 18F-FRP170 uptake in the lung cancer lesion could be visualized clearly from early after injection. The changes of tumor SUV, tumor/blood ratio, or tumor/muscle ratio about 30 min after injection or later were small.
  
  
  CONCLUSIONS
  Dynamic imaging using 18F-FRP170 demonstrated rapid elimination from the kidney, suggesting the high hydrophilicity of this imaging agent. The background activity above the diaphragm was very low, and patients with lung cancer showed clear tumor uptake of 18F-FRP170 early after injection.
authors.affiliation: Department of Diagnostic Radiology, Tohoku University, Sendai, Japan. kaneta@rad.med.tohoku.ac.jp
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kaneta
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Takai
authors.forename: Ren
authors.initials: R
authors.lastname: Iwata
authors.forename: Takashi
authors.initials: T
authors.lastname: Hakamatsuka
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yasuda
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Nakayama
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Shoichi
authors.initials: S
authors.lastname: Watanuki
authors.forename: Shozo
authors.initials: S
authors.lastname: Furumoto
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Funaki
authors.forename: Eiko
authors.initials: E
authors.lastname: Nakata
authors.forename: Keiichi
authors.initials: K
authors.lastname: Jingu
authors.forename: Michihiko
authors.initials: M
authors.lastname: Tsujitani
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Ito
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fukuda
authors.forename: Shoki
authors.initials: S
authors.lastname: Takahashi
authors.forename: Shogo
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000493:pharmacokinetics*; D009928:Organ Specificity; D010865:Pilot Projects; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014018:Tissue Distribution; D051598:Whole Body Imaging / Q000379:methods*
chemical_list: C501635:FRP-170; D009593:Nitroimidazoles; D019275:Radiopharmaceuticals